sales@dcchemicals.com
HI-62
Formulation & Performance
Formulation & Performance
Study-specific compositions, preparation conditions and experimental outcomes for HI-62.
Limited source access: the existing product record has been reorganized. Full-text and supplementary-file re-verification remains pending; numerical results below are retained from that earlier record and are not newly independently verified.
1. Formulations and component amounts
Reported composition and calculated mass are separate. Molecular-weight inputs use the current catalog values; DMG-PEG2000 is fixed initially at 2507. Edit inputs only when using a verified alternative material.
E21
Exact composition not recoveredEarlier HI-62 product record; preprint full text pending
| Component | Molecular weight | Reported molar entry | Calculated mass |
|---|---|---|---|
| HI-62 | 851.42 | Not recovered | Not calculated |
| Other formulation components | Not confirmed | Not recovered | Not calculated |
No complete mass recipe is generated for this formulation while composition or identity-dependent inputs remain unresolved.
How component weights are calculated
For total lipid mass M (mg), molar parts rᵢ and molecular weight MWᵢ: component mass = M × rᵢ × MWᵢ / Σ(r × MW). Component amount (µmol) = component mass (mg) × 1000 / MWᵢ. Molar parts are normalized only for the displayed percentage. The calculation does not infer N/P or RNA dose.
2. Preparation and experimental setup
| Parameter | Reported procedure / limitation | Source |
|---|---|---|
| Mixing | Earlier record: microfluidic mixing; organic:aqueous 1:3; total flow 20 mL/min. | Earlier record; primary-method check pending |
| N/P | Earlier record: 3–7 screened, with approximately 97% encapsulation at N/P 3. | Earlier record; primary-method check pending |
| Reproduction gaps | Exact helper-lipid identities and molar fractions, buffer composition/pH, purification, and formulation-to-assay mapping have not been recovered. | Not filled by inference |
3. Particle characterization
| Measurement / batch | Reported result | Evidence context |
|---|---|---|
| E21 particle size | 89.3 ± 0.6 nm | Earlier record; statistical basis pending |
| PDI / encapsulation | 0.03 / 97.5% | Earlier record; primary-table check pending |
| Apparent particle pKa | 6.45, TNS assay | Earlier record; assay conditions pending |
4. Performance by experiment
| Experiment and dose | Readout and comparator | Result and source |
|---|---|---|
| Reporter expression Mouse; FLuc mRNA; intravenous; 5 µg per mouse | Readout: 48 h Comparator: SM-102 formulation | Earlier record reports >1,000-fold higher expression. Animal number, organ normalization and comparator recipe require primary-source confirmation.Earlier product record; figure not re-verified |
| Freeze–thaw response RNA-loaded E21; six cycles | Readout: After six cycles; temperature protocol pending Comparator: SM-102 formulation | Earlier record reports >95% encapsulation versus a comparator change from 96% to <90%. Expression after cycling is not established here.Earlier product record; source check pending |
| Tumor study TC-1 mouse model; mRNA 10 µg per dose on days 0, 5 and 10 | Readout: Response-assessment date pending Comparator: Comparator details pending | Earlier record reports complete responses in 4/5 mice. Cargo identity, tumor schedule and response definition must be checked before protocol reuse.Earlier product record; source check pending |
Mechanistic evidence
A thiourea-containing ionizable lipid is described in the earlier product record. Structure-based hypotheses are not substituted for measured uptake or endosomal-escape data.
5. Interpretation and unresolved details
- The cited work is a preprint, not a peer-reviewed clinical study.
- This guide does not provide a complete reproducible E21 recipe. A component-mass calculation is withheld because the composition is missing.
- The full text and SI are required to resolve the assay conditions and source locations.
Results apply to the stated LNP composition, cargo, process, dose, route and model. LNP experimental measurements are not batch-release specifications for the isolated lipid.
6. References and data access
Zhang L, Huang Z, et al. Cyclic-thiourea ionizable lipids program multilamellar mRNA-LNPs for sustained expression, frozen-storage stability and potent vaccine immunotherapy. bioRxiv, 9 September 2026 (preprint).
DOI: 10.64898/2026.09.07.749752
Download experiment table (CSV) · Open printable Formulation & Performance guide
Revision FP-20261022 · Source review: 22 October 2026 · DC Chemicals